TABLE 4.

ECLIPSE/NORWAY COHORT/NETT META-ANALYSIS OF EMPHYSEMA QUANTITATIVE TRAIT WITH CORRECTION FOR BODY MASS INDEX: LOCI WITH META-ANALYSIS P VALUE < 10−5

			Closest Gene	Risk/Nonrisk Allele	Risk Allele Frequency	ECLIPSE		Norway		NETT		Meta P Value*	Meta β (P Value)†	Hetero-geneity I2 (%)
SNP	Chr	Type				β	P Value	β	P Value	β	P Value
rs7905537	10	Intergenic	PARD3	A/C	0.75	2.22	4.0 × 10−6	1.14	0.17	1.40	0.10	6.8 × 10−7	1.85 (8.1 × 10−7)	0
rs9292394	5	Intergenic	CDH6	T/G	0.78	1.35	6.6 × 10−3	2.96	5.3 × 10−4	2.21	0.02	3.5 × 10−6	1.83 (2.1 × 10−6)	31
rs7911712	10	In noncoding gene‡	AL139119.2	A/G	0.15	1.60	4.4 × 10−3	3.51	6.5 × 10−4	2.11	0.07	5.4 × 10−6	2.05 (5.5 × 10−6)	25
rs224731	10	Intergenic	PARD3	A/G	0.71	1.75	1.4 × 10−4	1.50	6.7 × 10−2	1.36	0.10	6.0 × 10−6	1.63 (6.4 × 10−6)	0

Definition of abbreviations: Chr = chromosome; ECLIPSE = Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; NETT = National Emphysema Treatment Trial; SNP = single-nucleotide polymorphism; β = regression coefficient under an additive genetic model.

^*Based on weighted Z-score method.

^†Based on fixed-effects meta-regression; I²: I² index used to assess magnitude of heterogeneity of b among studies.

^‡The SNP is located within a noncoding gene; the transcript of the gene is not translated into a protein and is classified as “processed transcript” in Ensembl.